Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Iron deficiency focused Shield Therapeutics said it had appointed current director Hans Peter Hasler as its new chairman.
Hasler had joined the company's board in July 2018 and was a previous chief operating officer at both Elan Corporation and Biogen.
He would on 18 June replace current chairman James Karis, who's pending departure was announced last week.
At 8:02am: (LON:STX) Shield Therapeutics PLC share price was 0p at 92.5p